CML: Nilotinib Yields High One-Year Survival in Accelerated-Phase Patients Resistant to Imatinibdoi:10.1097/01.COT.0000303250.86685.5eFuerst, MarkOncology Times
[11, 12] The IRIS investigators reported that patients with BCR-ABL transcripts of >10% at 6 months and >1% at 12 months had inferior EFS and higher rate of progression to accelerated- or blast-phase CML, while those with an MMR (BCR-ABL1≤ 0.1%) by 18 months had no progression to...
especially again in the first year. We’ve learned that there’s no statistically significant difference in survival, but if you look at CML-related deaths, there was clearly a decrease in the number of CML-related deaths that was not offset completely by other non-CML-related deaths, includi...
These agents have improved the 10-year survival rate from 20% to approximately 80% to 90%. TKIs have transformed CML f... NJ Short,E Jabbour,G Etienne,... - 《Clinical Advances in Hematology & Oncology H & O》 被引量: 0发表: 2017年 Stem cell persistence in chronic myeloid leukemia ...
You know, sometimes there’s the argument that, well, they don’t improve survival. Well, no, you know, with imatinib you’ve already reached near normal life expectancy, so, now we’re looking beyond just the survival benefit. And so, I prefer a second-generation TKI, and bosutinib ...
States, there are approximately 6,000 new cases of CML each year, with one-fourth of patients dying within two years. CML is divided into three stages: chronic phase, accelerated phase, and blast crisis phase, with an average survival of only 2-3 months in patients in blast crisis phase....
Some patients with CML progress to a transitional or accelerated phase, which may last for several months. The survival of patients diagnosed in this phase is 1-1.5 years. This phase is characterized by poor control of blood counts with therapy and the appearance of peripheral blast cells (≥...
Patients were also stratified by European Treatment and Outcome Study longterm survival score category (low, intermediate, or high risk) and TKI therapy selected by investigators before random assignment (imatinib and second-generation TKIs). For the primary end point of the stu...
(CCyR 76.2% vs. 14.5%,P<.001) at 18 months. Shortly after this notable finding emerged, imatinib became the standard of care for CML. After 8 years of follow-up, imatinib continues to produce durable responses, with a projected overall survival (OS) of 85% and a low rate of ...
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. We studied the influence of comorbidities on remission rate and overall survival (OS) in patients with chronic myeloid leukemia (CML). Participants of the ... S Saussele...